David Pendarvis - ResMed Executive
| RMD Stock | USD 183.78 0.44 0.24% |
Executive
Mr. David Pendarvis is Chief Administrative Officer, Global General Counsel and Secretary of the Company. He was chief administrative officer and global general counsel since May 2011. He served as interim president for ResMed EMEA and Japan from March to August 2017, in addition to his chief administrative officer and global general counsel roles. Mr. Pendarvis joined ResMed as global general counsel in September 2002, and was corporate secretary since February 2003. From February 2005 to May 2011, he served as senior vice president of organizational development. Before joining ResMed, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware Freidenrich LLP, from September 2000 until September 2002, where he specialized in intellectual property and general business litigation. From 1986 to 2000, he was a partner with Gibson, Dunn Crutcher LLP. From 1984 to 1986 he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Since 2017, Mr. Pendarvis has served on the board of directors of WD40 Company, a global marketing organization dedicated to creating positive lasting memories by developing and selling products that solve problems in workshops, factories and homes around the world. He has also served on the board of directors of the San Diego Regional Chamber of Commerce since 2013 and the Corporationrationrate Directors Forum since 2010. From 2009 to 2016, he was a director on the board of Sequenom, Inc since 2011.
| Age | 65 |
| Tenure | 13 years |
| Address | 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 |
| Phone | 858-836-5000 |
| Web | https://www.resmed.com |
ResMed Management Efficiency
The company has Return on Asset of 0.1119 % which means that on every $100 spent on assets, it made $0.1119 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2166 %, implying that it generated $0.2166 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to 0.13. In addition to that, Return On Capital Employed is expected to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 477.5 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Christopher Toth | Baxter International | 44 | |
| MS MD | Baxter International | N/A | |
| Brian Moore | STAAR Surgical | N/A | |
| JoAnne Alkire | Merit Medical Systems | N/A | |
| Rudy Poussot | West Pharmaceutical Services | N/A | |
| Shana Neal | Becton Dickinson and | 58 | |
| Nicholas Khadder | The Cooper Companies | 50 | |
| Michelle Fox | Teleflex Incorporated | N/A | |
| Ryan Simon | Hologic | N/A | |
| Denise McEachern | STAAR Surgical | 55 | |
| Carla Burigatto | Becton Dickinson and | N/A | |
| John Mills | ICU Medical | N/A | |
| Greg Rodetis | Becton Dickinson and | N/A | |
| Elizabeth McCombs | Becton Dickinson and | 48 | |
| Shaun Curtis | Embecta Corp | 55 | |
| Denise Fleming | Becton Dickinson and | 54 | |
| Howard Cyr | Teleflex Incorporated | N/A | |
| Piero Novello | Baxter International | N/A | |
| Colleen Riley | Embecta Corp | 60 | |
| John Griffin | Hologic | 63 | |
| Heather Knight | Baxter International | 52 | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.11 |
ResMed Inc Leadership Team
Elected by the shareholders, the ResMed's board of directors comprises two types of representatives: ResMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ResMed. The board's role is to monitor ResMed's management team and ensure that shareholders' interests are well served. ResMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ResMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bobby Ghoshal, Chief Technology Officer, President - SaaS business | ||
| AM BE, Chair Founder | ||
| John Wareham, Independent Director | ||
| Ronald Taylor, Lead Independent Director | ||
| Michael Rider, Chief Officer | ||
| Gary Pace, Independent Director | ||
| Agnes Lee, Senior Director - Investor Relations | ||
| Vered Keisar, Chief Officer | ||
| Harjit Gill, Independent Director | ||
| Kaushik Ghoshal, Chief SaaS | ||
| Carol Burt, Independent Director | ||
| Rich Sulpizio, Independent Director | ||
| Peter Farrell, Non-Executive Chairman of the Board | ||
| Jim Hollingshead, President – sleep and respiratory care business | ||
| Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit | ||
| Jack Wareham, Independent Director | ||
| Jan Witte, Independent Director | ||
| Rajwant Sodhi, President – Software as a Service Business (SaaS) | ||
| BE MBA, CEO Director | ||
| Anne Reiser, President Europe | ||
| Karen Drexler, Independent Director | ||
| AM AM, Founder Chairman | ||
| Richard McHale, President – Respiratory Care Business | ||
| Donald Darkin, President – innovation & operations | ||
| Constance Bienfait, Director Relations | ||
| Urvashi Tyagi, Chief Technology Officer | ||
| Rob Douglas, President COO | ||
| Justin Leong, President – Asia and Latin America | ||
| Christopher Roberts, Independent Director | ||
| Chris Roberts, Independent Director | ||
| Robert Douglas, President, Chief Operating Officer | ||
| YvonneKatrin Pucknat, Chief Officer | ||
| Amy Wakeham, VP Communications | ||
| Brett Sandercock, CFO and Principal Accounting Officer | ||
| Ron Taylor, Lead Independent Director | ||
| Raj Sodhi, President – Software as a Service (SaaS) Business and CTO | ||
| David Pendarvis, Chief Administrative Officer, Global General Counsel, Secretary | ||
| Richard Sulpizio, Independent Director | ||
| Michael Farrell, Chief Executive Officer, Director | ||
| Jim Ellis, Chief Officer |
ResMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ResMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 28.27 B | ||||
| Shares Outstanding | 147.09 M | ||||
| Shares Owned By Insiders | 0.81 % | ||||
| Shares Owned By Institutions | 57.23 % | ||||
| Number Of Shares Shorted | 7.89 M | ||||
| Price To Earning | 73.48 X |
ResMed Investors Sentiment
The influence of ResMed's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in ResMed. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to ResMed's public news can be used to forecast risks associated with an investment in ResMed. The trend in average sentiment can be used to explain how an investor holding ResMed can time the market purely based on public headlines and social activities around ResMed Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ResMed's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ResMed's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average ResMed's news discussions. The higher the estimated score, the more favorable is the investor's outlook on ResMed.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ResMed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ResMed's short interest history, or implied volatility extrapolated from ResMed options trading.
Currently Active Assets on Macroaxis
When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is ResMed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Dividend Share 1.84 | Earnings Share 6.04 | Revenue Per Share 30.633 | Quarterly Revenue Growth 0.125 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.